



Sample Information

Patient Name: 許又文
Gender: Female
ID No.: C221342893
History No.: 44468384
Age: 29

Ordering Doctor: DOC1654E 林庭安
Ordering REQ.: 0BBDFWC
Signing in Date: 2021/01/21

Path No.: S110-98096
MP No.: F21005
Assay: Oncomine Focus Assay
Sample Type: FFPE
Block No.: S110-01592A
Percentage of tumor cells: 60%
Note:

Sample Cancer Type: Melanoma

| Table of Contents | Page |
|--------------------------|------|
| Variant Details | 2 |
| Biomarker Descriptions | 3 |
| Relevant Therapy Summary | 4 |
| Relevant Therapy Details | 6 |
| Clinical Trials Summary | 20 |
| Alert Details | 23 |

Report Highlights

2 Relevant Biomarkers
11 Therapies Available
60 Clinical Trials

Relevant Melanoma Variants

| Gene | Finding |
|-------|---|
| BRAF | <i>BRAF p.(V600E) c.1799T>A</i> |
| KIT | Not detected |
| NTRK1 | Not detected |
| NTRK2 | Not detected |
| NTRK3 | Not detected |

Relevant Biomarkers

| Tier | Genomic Alteration | Relevant Therapies (In this cancer type) | Relevant Therapies (In other cancer type) | Clinical Trials |
|------|---|--|--|-----------------|
| IA | BRAF p.(V600E) c.1799T>A B-Raf proto-oncogene, serine/threonine kinase Allele Frequency: 47.06% | atezolizumab + cobimetinib + vemurafenib ¹ binimetinib + encorafenib ^{1, 2} cetuximab + encorafenib ^{1, 2} cobimetinib + vemurafenib ^{1, 2} dabrafenib ^{1, 2} dabrafenib + trametinib ^{1, 2} trametinib ^{1, 2} vemurafenib ^{1, 2} BRAF inhibitor + MEK inhibitor ipilimumab + nivolumab | binimetinib + encorafenib ^{1, 2} cetuximab + encorafenib ^{1, 2} dabrafenib ^{1, 2} dabrafenib + trametinib ^{1, 2} trametinib ^{1, 2} encorafenib + panitumumab vemurafenib | 57 |
| | MYC amplification MYC proto-oncogene, bHLH transcription factor | None | None | 3 |

Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Variant Details

DNA Sequence Variants

| Gene | Amino Acid Change | Coding | Variant ID | Locus | Allele Frequency | Transcript | Variant Effect | Coverage |
|--------|-------------------|-----------|------------|----------------|------------------|----------------|----------------|----------|
| BRAF | p.(V600E) | c.1799T>A | COSM476 | chr7:140453136 | 47.06% | NM_004333.4 | missense | 1987 |
| JAK1 | p.(=) | c.2199A>G | . | chr1:65310489 | 60.73% | NM_002227.3 | synonymous | 1981 |
| ALK | p.(D1529E) | c.4587C>G | . | chr2:29416366 | 59.82% | NM_004304.4 | missense | 1996 |
| ALK | p.(I1461V) | c.4381A>G | . | chr2:29416572 | 99.85% | NM_004304.4 | missense | 1999 |
| ALK | p.(=) | c.3375C>A | . | chr2:29445458 | 64.03% | NM_004304.4 | synonymous | 1996 |
| FGFR3 | p.(=) | c.1953G>A | . | chr4:1807894 | 99.60% | NM_000142.4 | synonymous | 1516 |
| PDGFRA | p.(=) | c.939T>G | . | chr4:55133726 | 47.89% | NM_006206.5 | synonymous | 1994 |
| PDGFRA | p.(=) | c.1701A>G | . | chr4:55141055 | 99.95% | NM_006206.5 | synonymous | 1999 |
| FGFR4 | p.(P136L) | c.407C>T | . | chr5:176517797 | 99.65% | NM_213647.2 | missense | 1999 |
| EGFR | p.(=) | c.2361G>A | . | chr7:55249063 | 59.13% | NM_005228.4 | synonymous | 1999 |
| MET | p.(N375S) | c.1124A>G | . | chr7:116340262 | 58.13% | NM_001127500.2 | missense | 1999 |
| RET | p.(=) | c.2307G>T | . | chr10:43613843 | 100.00% | NM_020975.4 | synonymous | 1994 |
| RET | p.(=) | c.2712C>G | . | chr10:43615633 | 78.46% | NM_020975.4 | synonymous | 1996 |
| BRCA1 | p.(=) | c.5373G>A | . | chr17:41203102 | 63.13% | NM_007300.3 | synonymous | 1999 |

Copy Number Variations

| Gene | Locus | Copy Number |
|------|----------------|-------------|
| MYC | chr8:128748885 | 5.13 |

Biomarker Descriptions

BRAF (B-Raf proto-oncogene, serine/threonine kinase)

Background: The BRAF gene encodes the B-Raf proto-oncogene serine/threonine kinase, a member of the RAF family of serine/threonine protein kinases which also includes ARAF and RAF1 (CRAF). BRAF is among the most commonly mutated kinases in cancer. Activation of the MAPK pathway occurs through BRAF mutations and leads to an increase in cell division, dedifferentiation, and survival^{1,2}. BRAF mutations are categorized into three distinct functional classes namely, class 1, 2, and 3, and are defined by the dependency on the RAS pathway. Class 1 and 2 BRAF mutants are RAS-independent in that they signal as active monomers (Class 1) or dimers (Class 2) and become uncoupled from RAS GTPase signaling, resulting in constitutive activation of BRAF³. Class 3 mutants are RAS dependent as the kinase domain function is impaired or dead^{3,4,5}.

Alterations and prevalence: Recurrent somatic mutations in BRAF are observed in 40-60% of melanoma and thyroid cancer, approximately 10% of colorectal cancer, and about 2% of non-small cell lung cancer (NSCLC)^{6,7,8,9,10}. Mutations at V600 belong to class 1 and include V600E, the most recurrent somatic BRAF mutation across diverse cancer types^{4,11}. Class 2 mutations include K601E/N/T, L597Q/V, G469A/V/R/, G464V/E/, and BRAF fusions⁴. Class 3 mutations include D287H, V459L, G466V/E/A, S467L, G469E, and N581S/I⁴. BRAF V600E is universally present in hairy cell leukemia, mature B-cell cancer, and prevalent in histiocytic neoplasms^{12,13,14}. Other recurrent BRAF somatic mutations cluster in the glycine-rich phosphate-binding loop at codons 464-469 in exon 11 as well as additional codons flanking V600 in the activation loop¹¹. In primary cancers, BRAF amplification is observed in 8% of ovarian cancer and about 1% of breast cancer^{7,10}. BRAF fusions are mutually exclusive to BRAF V600 mutations and have been described in melanoma, thyroid cancer, pilocytic astrocytoma, NSCLC, and several other cancer types^{15,16,17,18,19}. Part of the oncogenic mechanism of BRAF gene fusions is the removal of the N-terminal auto-inhibitory domain leading to constitutive kinase activation^{5,15,17}.

Potential relevance: Vemurafenib²⁰ (2011) was the first targeted therapy approved for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation. BRAF class 1 mutations, including V600E, are sensitive to vemurafenib, whereas class 2 and 3 mutations are insensitive⁴. BRAF kinase inhibitors including dabrafenib²¹ (2013) and encorafenib²² (2018) are also approved for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E/K mutations. Encorafenib²² is approved in combination with cetuximab (2020) for the treatment of BRAF V600E mutated colorectal cancer. Due to the tight coupling of RAF and MEK signaling, several MEK inhibitors have been approved for patients harboring BRAF alterations⁴. Trametinib²³ (2013) and binimetinib²⁴ (2018) were approved for the treatment of metastatic melanoma with BRAF V600E/K mutations. Combination therapies of BRAF plus MEK inhibitors have been approved in melanoma and NSCLC. The combinations of dabrafenib and trametinib (2015) and vemurafenib and cobimetinib²⁵ (2015) were approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation. Subsequently, the combination of dabrafenib and trametinib was approved for metastatic NSCLC (2017) with a BRAF V600E mutation. The ERK inhibitor ulixertinib²⁶ was granted a fast track designation in 2020 for the treatment of patients with non-colorectal solid tumors harboring BRAF mutations G469A/V, L485W, or L597Q. BRAF amplification, alternative splice transcripts, and BRAF fusions are suggested mechanisms of resistance to BRAF targeted therapy in melanoma^{27,28,29,30}. Other mechanisms of resistance include activating mutations in KRAS, NRAS, and MAP2K1/2 (MEK1/2) as well as activation of PI3K signaling^{29,31,32,33,34}. Clinical responses to sorafenib and trametinib in limited case studies of patients with BRAF fusions have been reported¹⁹.

MYC (MYC proto-oncogene, bHLH transcription factor)

Background: The MYC gene encodes the MYC proto-oncogene (c-MYC), a basic helix-loop-helix transcription factor that regulates the expression of numerous genes that control cell cycle progression, apoptosis, metabolic pathways, and cellular transformation^{35,36,37,38}. MYC is part of the MYC oncogene family that includes related transcription factors MYCN and MYCL that regulate transcription in 10-15% of promoter regions³⁹. MYC functions as a heterodimer in complex with the transcription factor MAX^{36,40}.

Alterations and prevalence: Recurrent somatic alterations are observed in both solid and hematological cancers. Recurrent somatic mutations in MYC, including codon T58, are infrequent and hypothesized to increase the stability of the MYC protein^{41,42}. MYC gene amplification is particularly common in diverse solid tumors. MYC amplification is observed in 30% of serous ovarian cancer, 20% of uterine serous carcinoma, 15% of esophageal and breast cancers, and is common (1-10%) in numerous other cancer types^{7,43,44}. MYC is the target of the t(8;14)(q24;32) chromosomal translocation in Burkitt's lymphoma that places MYC coding sequences adjacent to immunoglobulin region regulatory sequences, which results in increased MYC expression^{45,46}.

Potential relevance: Currently, no therapies are approved for MYC aberrations. Due to the high frequency of somatic MYC alterations in cancer, many approaches are being investigated in clinical trials including strategies to disrupt complex formation with MAX, including inhibition of MYC expression and synthetic lethality associated with MYC overexpression^{35,47,48,49}.

Relevant Therapy Summary

● In this cancer type
 ○ In other cancer type
 ● In this cancer type and other cancer types
 ✕ No evidence

BRAF p.(V600E) c.1799T>A

| Relevant Therapy | FDA | NCCN | EMA | ESMO | Clinical Trials* |
|---|-----|------|-----|------|------------------|
| dabrafenib + trametinib | ● | ● | ● | ● | ✕ |
| dabrafenib | ● | ● | ● | ✕ | ✕ |
| binimetinib + encorafenib | ● | ● | ● | ● | ✕ |
| cetuximab + encorafenib | ● | ○ | ● | ✕ | ✕ |
| trametinib | ● | ✕ | ● | ✕ | ✕ |
| vemurafenib | ● | ● | ● | ✕ | ● (II) |
| cobimetinib + vemurafenib | ● | ● | ● | ● | ● (II) |
| atezolizumab + cobimetinib + vemurafenib | ● | ✕ | ✕ | ✕ | ✕ |
| encorafenib + panitumumab | ✕ | ○ | ✕ | ✕ | ✕ |
| BRAF inhibitor + MEK inhibitor | ✕ | ✕ | ✕ | ● | ✕ |
| ipilimumab + nivolumab | ✕ | ✕ | ✕ | ● | ✕ |
| bempegaldesleukin, nivolumab | ✕ | ✕ | ✕ | ✕ | ● (III) |
| dabrafenib, trametinib, ipilimumab, nivolumab | ✕ | ✕ | ✕ | ✕ | ● (III) |
| relatlimab, nivolumab | ✕ | ✕ | ✕ | ✕ | ● (II/III) |
| sargramostim, nivolumab, ipilimumab | ✕ | ✕ | ✕ | ✕ | ● (II/III) |
| atezolizumab, cobimetinib, vemurafenib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| binimetinib, encorafenib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| buparlisib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| cobimetinib, atezolizumab, vemurafenib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| cobimetinib, vemurafenib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| dabrafenib + pembrolizumab + trametinib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| dabrafenib, nivolumab, trametinib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| dabrafenib, pembrolizumab, trametinib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| dabrafenib, trametinib | ✕ | ✕ | ✕ | ✕ | ● (II) |
| dabrafenib, trametinib, spartalizumab | ✕ | ✕ | ✕ | ✕ | ● (II) |
| IMM-101, nivolumab, ipilimumab | ✕ | ✕ | ✕ | ✕ | ● (II) |
| immunostimulant, pembrolizumab | ✕ | ✕ | ✕ | ✕ | ● (II) |
| ipilimumab, binimetinib, nivolumab, encorafenib | ✕ | ✕ | ✕ | ✕ | ● (II) |

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

 In this cancer type
  In other cancer type
  In this cancer type and other cancer types
  No evidence

BRAF p.(V600E) c.1799T>A (continued)

| Relevant Therapy | FDA | NCCN | EMA | ESMO | Clinical Trials* |
|---|-----|------|-----|------|------------------|
| ipilimumab, nivolumab, encorafenib, binimetinib, dabrafenib, trametinib | × | × | × | × | ● (II) |
| LXH254, LTT-462, trametinib, ribociclib | × | × | × | × | ● (II) |
| nivolumab, ipilimumab, radiation therapy | × | × | × | × | ● (II) |
| vemurafenib, cobimetinib | × | × | × | × | ● (II) |
| vemurafenib, cobimetinib, atezolizumab | × | × | × | × | ● (II) |
| vemurafenib, cobimetinib, ipilimumab, nivolumab | × | × | × | × | ● (II) |
| vemurafenib, cobimetinib, surgical intervention, radiation therapy | × | × | × | × | ● (II) |
| vemurafenib, dabrafenib | × | × | × | × | ● (II) |
| ASTX029 | × | × | × | × | ● (I/II) |
| bemcentinib, dabrafenib, pembrolizumab, trametinib | × | × | × | × | ● (I/II) |
| dabrafenib, trametinib, antimalarial | × | × | × | × | ● (I/II) |
| dabrafenib, trametinib, navitoclax | × | × | × | × | ● (I/II) |
| HH-2710 | × | × | × | × | ● (I/II) |
| lacnotuzumab, trametinib, dabrafenib | × | × | × | × | ● (I/II) |
| mirdametinib, lifirafenib | × | × | × | × | ● (I/II) |
| vorinostat | × | × | × | × | ● (I/II) |
| ABM-1310 | × | × | × | × | ● (I) |
| BGB-3245 | × | × | × | × | ● (I) |
| CART-GD2, vemurafenib | × | × | × | × | ● (I) |
| cobimetinib, belvarafenib | × | × | × | × | ● (I) |
| E6201 | × | × | × | × | ● (I) |
| HL-085, vemurafenib | × | × | × | × | ● (I) |
| itacitinib, dabrafenib, trametinib | × | × | × | × | ● (I) |
| JAB-3312 | × | × | × | × | ● (I) |
| JSI-1187, dabrafenib | × | × | × | × | ● (I) |
| LY3214996, midazolam, abemaciclib, chemotherapy, encorafenib, cetuximab | × | × | × | × | ● (I) |
| MLN-2480 | × | × | × | × | ● (I) |

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

BRAF p.(V600E) c.1799T>A (continued)

| Relevant Therapy | FDA | NCCN | EMA | ESMO | Clinical Trials* |
|------------------------|-----|------|-----|------|------------------|
| RG-7461, pembrolizumab | × | × | × | × | ● (I) |
| RMC-4630 | × | × | × | × | ● (I) |
| RO-5126766, everolimus | × | × | × | × | ● (I) |
| RX208 | × | × | × | × | ● (I) |
| TQ-B3233 | × | × | × | × | ● (I) |

MYC amplification

| Relevant Therapy | FDA | NCCN | EMA | ESMO | Clinical Trials* |
|-----------------------|-----|------|-----|------|------------------|
| berzosertib | × | × | × | × | ● (II) |
| entinostat, nivolumab | × | × | × | × | ● (I/II) |
| BMS-986158 | × | × | × | × | ● (I) |

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

FDA information is current as of 2020-11-18. For the most up-to-date information, search www.fda.gov.

BRAF p.(V600E) c.1799T>A

☒ binimetinib + encorafenib, cetuximab + encorafenib

Cancer type: Colorectal Cancer, Melanoma

Label as of: 2020-04-08

Variant class: BRAF V600E mutation

Indications and usage:

BRAFTOVI® is a kinase inhibitor indicated:

- in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
- in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Limitations of Use: BRAFTOVI® is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf

BRAF p.(V600E) c.1799T>A (continued)

① dabrafenib, dabrafenib + trametinib

Cancer type: Melanoma, Non-Small Cell Lung Cancer, Thyroid Gland Anaplastic Carcinoma
Label as of: 2020-04-09

Variant class: BRAF V600E mutation

Indications and usage:

TAFINLAR® is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

TAFINLAR® is indicated, in combination with trametinib, for:

- the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
- the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
- the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
- the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Limitations of Use: TAFINLAR® is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf

① trametinib, dabrafenib + trametinib

Cancer type: Melanoma, Non-Small Cell Lung Cancer, Thyroid Gland Anaplastic Carcinoma
Label as of: 2020-06-23

Variant class: BRAF V600E mutation

Indications and usage:

MEKINIST® is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.

MEKINIST® is indicated, in combination with dabrafenib, for:

- the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
- the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
- the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
- the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf

BRAF p.(V600E) c.1799T>A (continued)

● atezolizumab + cobimetinib + vemurafenib

Cancer type: Melanoma

Label as of: 2020-11-10

Variant class: BRAF V600E mutation

Indications and usage:

TECENTRIQ® is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:

Urothelial Carcinoma

- for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
 - are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area), as determined by an FDA-approved test, or
 - are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status, or
 - have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Non-Small Cell Lung Cancer (NSCLC)

- for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
- in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
- in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations
- for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ®

Triple-Negative Breast Cancer (TNBC)

- in combination with paclitaxel protein-bound for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area), as determined by an FDA approved test. This indication is approved under accelerated approval based on progression free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Small Cell Lung Cancer (SCLC)

- in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Hepatocellular Carcinoma (HCC)

- in combination with bevacizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy

Melanoma

- in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s020lbl.pdf

BRAF p.(V600E) c.1799T>A (continued)**● binimetinib + encorafenib****Cancer type:** Melanoma**Label as of:** 2019-01-23**Variant class:** BRAF V600E mutation**Indications and usage:**

MEKTOVI® is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210498s001lbl.pdf

● cobimetinib + vemurafenib**Cancer type:** Melanoma**Label as of:** 2018-01-26**Variant class:** BRAF V600E mutation**Indications and usage:**

COTELLIC® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf

● vemurafenib**Cancer type:** Melanoma**Label as of:** 2020-05-18**Variant class:** BRAF V600E mutation**Indications and usage:**

- ZELBORAF® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
- ZELBORAF® is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.

Limitation of Use: ZELBORAF® is not indicated for treatment of patients with wild-type BRAF melanoma.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf

Current NCCN Information

- ☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

NCCN information is current as of 2020-11-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

BRAF p.(V600E) c.1799T>A

● dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Melanoma; Brain metastases; Use active agents against primary tumor (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2020]

● cobimetinib + vemurafenib

Cancer type: Melanoma

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Melanoma; Brain metastases; Use active agents against primary tumor (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2020]

● binimetinib + encorafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma (First-line therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● cobimetinib + vemurafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma (First-line therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

BRAF p.(V600E) c.1799T>A (continued)**● dabrafenib + trametinib**

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Cutaneous Melanoma; Stage III clinically positive nodes (Adjuvant therapy) (Preferred)
- Cutaneous Melanoma; Nodal recurrence; No previous lymph node dissection (Adjuvant therapy) (Preferred)
- Cutaneous Melanoma; Disease limited to nodal recurrence; After complete resection (Adjuvant therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma (First-line therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● binimetinib + encorafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma; Progression or maximum clinical benefit from BRAF targeted therapy (Second-line or subsequent therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● cobimetinib + vemurafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma (First-line therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

BRAF p.(V600E) c.1799T>A (continued)

● cobimetinib + vemurafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma; Progression or maximum clinical benefit from BRAF targeted therapy (Second-line or subsequent therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● dabrafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma; If BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy with dabrafenib or vemurafenib are recommended options, especially when checkpoint immunotherapy is not appropriate (First, second-line or subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Cutaneous Melanoma; Stage IIIA-D sentinel node positive (Adjuvant therapy) (Preferred)
- Cutaneous Melanoma; Stage III clinical satellite/in-transit; No evidence of disease following resection (Adjuvant therapy) (Preferred)
- Cutaneous Melanoma; Local satellite/in-transit recurrence; No evidence of disease following resection (Adjuvant therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma; Progression or maximum clinical benefit from BRAF targeted therapy (Second-line or subsequent therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

BRAF p.(V600E) c.1799T>A (continued)**● vemurafenib**

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic or Unresectable Cutaneous Melanoma; If BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy with dabrafenib or vemurafenib are recommended options, especially when checkpoint immunotherapy is not appropriate (First, second-line or subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● binimetinib + encorafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Resectable Distant Metastatic Cutaneous Melanoma; No evidence of disease (Adjuvant therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● cobimetinib + vemurafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Resectable Distant Metastatic Cutaneous Melanoma; No evidence of disease (Adjuvant therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

● dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Resectable Distant Metastatic Cutaneous Melanoma; No evidence of disease (Adjuvant therapy) (Other recommended regimen)

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

BRAF p.(V600E) c.1799T>A (continued)

○ cetuximab + encorafenib

Cancer type: Colon Cancer

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable Metachronous Metastatic Colon Cancer; Previous adjuvant FOLFOX/CAPEOX within past 12 months (Primary therapy)
- Advanced or Metastatic Colon Cancer; Progression after initial therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 4.2020]

○ cetuximab + encorafenib

Cancer type: Rectal Cancer

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable Metachronous Metastatic Rectal Cancer; Previous adjuvant FOLFOX/CAPEOX within past 12 months (Primary therapy)
- Advanced or Metastatic Rectal Cancer; Progression after initial therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 6.2020]

○ dabrafenib

Cancer type: Non-Small Cell Lung Cancer

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease (First-line therapy) (Other Recommended)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]

○ dabrafenib + trametinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease (First-line therapy) (Preferred)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]

BRAF p.(V600E) c.1799T>A (continued)

○ dabrafenib + trametinib

Cancer type: Thyroid Gland Anaplastic Carcinoma **Variant class:** BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Thyroid Gland Anaplastic Carcinoma; Metastatic (Not specified) (Preferred)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]

○ encorafenib + panitumumab

Cancer type: Colon Cancer

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable Metachronous Metastatic Colon Cancer; Previous adjuvant FOLFOX/CAPEOX within past 12 months (Primary therapy)
- Advanced or Metastatic Colon Cancer; Progression after initial therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 4.2020]

○ encorafenib + panitumumab

Cancer type: Rectal Cancer

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable Metachronous Metastatic Rectal Cancer; Previous adjuvant FOLFOX/CAPEOX within past 12 months (Primary therapy)
- Advanced or Metastatic Rectal Cancer; Progression after initial therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 6.2020]

○ vemurafenib

Cancer type: Non-Small Cell Lung Cancer

Variant class: BRAF V600E mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease (First-line therapy) (Other Recommended)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]

BRAF p.(V600E) c.1799T>A (continued)**○ dabrafenib**

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma
Variant class: BRAF mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; Unresectable locoregional recurrent/persistent disease; Progressive and/or symptomatic disease if clinical trials or other systemic therapies are not available or appropriate (Not specified)
- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; CNS or soft tissue or bone metastases; Progressive and/or symptomatic disease if clinical trials or other systemic therapies are not available or appropriate (Not specified)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]

○ vemurafenib

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma
Variant class: BRAF mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; Unresectable locoregional recurrent/persistent disease; Progressive and/or symptomatic disease if clinical trials or other systemic therapies are not available or appropriate (Not specified)
- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; CNS or soft tissue or bone metastases; Progressive and/or symptomatic disease if clinical trials or other systemic therapies are not available or appropriate (Not specified)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]

Current EMA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

EMA information is current as of 2020-11-18. For the most up-to-date information, search www.ema.europa.eu/ema.

BRAF p.(V600E) c.1799T>A

☒ binimetinib + encorafenib, cetuximab + encorafenib

Cancer type: Colorectal Cancer, Melanoma

Label as of: 2020-06-16

Variant class: BRAF V600E mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf

☒ dabrafenib, dabrafenib + trametinib

Cancer type: Melanoma, Non-Small Cell Lung Cancer

Label as of: 2020-01-17

Variant class: BRAF V600E mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf

☒ trametinib, dabrafenib + trametinib

Cancer type: Melanoma, Non-Small Cell Lung Cancer

Label as of: 2020-08-18

Variant class: BRAF V600E mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf

☒ binimetinib + encorafenib

Cancer type: Melanoma

Label as of: 2019-10-04

Variant class: BRAF V600E mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf

☒ cobimetinib + vemurafenib

Cancer type: Melanoma

Label as of: 2020-07-07

Variant class: BRAF V600E mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf

☒ vemurafenib

Cancer type: Melanoma

Label as of: 2020-01-30

Variant class: BRAF V600E mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf

Current ESMO Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

ESMO information is current as of 2020-11-02. For the most up-to-date information, search www.esmo.org.

BRAF p.(V600E) c.1799T>A

● BRAF inhibitor + MEK inhibitor

Cancer type: Melanoma

Variant class: BRAF V600 mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):

- Cutaneous Melanoma; Unresectable stage III and IV; First-line immunotherapy is not safe (First-line therapy)
- Cutaneous Melanoma; asymptomatic brain metastases (Not specified)

Reference: ESMO Clinical Practice Guidelines - ESMO-Cutaneous Melanoma [Annals of Oncology 30: 1884–1901. doi:10.1093/annonc/mdz411]

● dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):

- Cutaneous Melanoma; After surgical resection; Stage IIIA (SN >1mm), IIIB and IIIC (Adjuvant therapy) (Preferred)

Reference: ESMO Clinical Practice Guidelines - ESMO-Cutaneous Melanoma [Annals of Oncology 30: 1884–1901. doi:10.1093/annonc/mdz411]

● binimetinib + encorafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):

- Cutaneous Melanoma; Unresectable stage III and IV (First or second-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Cutaneous Melanoma [Annals of Oncology 30: 1884–1901. doi:10.1093/annonc/mdz411]

● cobimetinib + vemurafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):

- Cutaneous Melanoma; Unresectable stage III and IV (First or second-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Cutaneous Melanoma [Annals of Oncology 30: 1884–1901. doi:10.1093/annonc/mdz411]

BRAF p.(V600E) c.1799T>A (continued)

● dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):

- Cutaneous Melanoma; Unresectable stage III and IV (First or second-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Cutaneous Melanoma [Annals of Oncology 30: 1884–1901. doi:10.1093/annonc/mdz411]

● ipilimumab + nivolumab

Cancer type: Melanoma

Variant class: BRAF V600 mutation

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):

- Cutaneous Melanoma; Unresectable stage III and IV; Asymptomatic brain metastases (First-line therapy) (Preferred)

Reference: ESMO Clinical Practice Guidelines - ESMO-Cutaneous Melanoma [Annals of Oncology 30: 1884–1901. doi:10.1093/annonc/mdz411]

○ dabrafenib + trametinib

Cancer type: Thyroid Gland Anaplastic Carcinoma Variant class: BRAF V600E mutation

ESMO Level of Evidence/Grade of Recommendation: V / B

Population segment (Line of therapy):

- Advanced or Unresectable Thyroid Gland Anaplastic Carcinoma (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Thyroid Cancer [Annals of Oncology 30: 1856–1883, 2019 doi:10.1093/annonc/mdz400]

○ dabrafenib + trametinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: BRAF V600 mutation

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):

- Stage IV; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 2 (First or second-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

Clinical Trials Summary

BRAF p.(V600E) c.1799T>A

| NCT ID | Title | Phase |
|-------------|--|-------|
| NCT03898908 | Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain. | II |
| NCT02858921 | A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma | II |
| NCT02231775 | Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo) | II |
| NCT04310397 | Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT) | II |
| NCT03235245 | Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN) | II |
| NCT02968303 | Phase II Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapy | II |
| NCT01989585 | Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only) | I/II |
| NCT03455764 | A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition | I/II |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | I/II |
| NCT04190628 | A Phase I, First-In-Human, Multicenter, Open-Label Study of ABM-1310, Administered Orally in Adult Patients With Advanced Solid Tumors | I |
| No NCT ID | Phase I Study of Safety and Immune Effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T cells in Patients with Metastatic Melanoma | I |
| NCT03272464 | Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors | I |
| NCT02224781 | DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial | III |
| NCT03554083 | Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial | II |
| NCT03911869 | A Phase II, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis | II |
| NCT02452294 | An Open-label, Uncontrolled, Single Arm Phase II Trial of Buparlisib in Patients With Metastatic Melanoma With Brain Metastases Not Eligible for Surgery or Radiosurgery | II |
| NCT02036086 | A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases | II |
| NCT03625141 | A Phase II Two Cohort Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases. | II |
| NCT03430947 | An Open-Label Phase II Multicenter Study Of Vemurafenib (Zelboraf) Plus Cobimetinib (Cotellic) After Radiosurgery In Patients With Active BRAF-V600-Mutant Melanoma Brain Metastases | II |

Clinical Trials Summary (continued)

BRAF p.(V600E) c.1799T>A (continued)

| NCT ID | Title | Phase |
|-------------|--|--------|
| NCT03149029 | A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma | II |
| No NCT ID | A Non-Intervention MultiCenter Study of the Combination Tafenlar (Dabrafenib) and Mekinist (Trametinib) in the Treatment of Malignant Melanoma | II |
| NCT04417621 | A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma | II |
| NCT03224208 | VECODUE A Phase II Trial of Vemurafenib Plus Cobimetinib in Patients Treated With Prior First-line Systemic Immunotherapy for Inoperable Locally Advanced or Metastatic Melanoma | II |
| NCT02303951 | Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC | II |
| NCT03514901 | An Evaluation of the Efficacy Beyond Progression of Vemurafenib Combined With Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600 Mutation-positive Metastatic Melanoma in Focal Progression With First-line Combined Vemurafenib and Cobimetinib. | II |
| NCT03754179 | A lead-in Phase I Followed by a Phase II Clinical Trial on the Combination of Dabrafenib, Trametinib and the Autophagy Inhibitor Hydroxychloroquine in BRAF/MEK Inhibitor-pretreated Patients With Advanced BRAF V600 Mutant Melanoma | I/II |
| NCT04249843 | A First-in-Human, Phase Ia/Ib, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors | I |
| NCT03284502 | A Phase Ib, Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors | I |
| NCT03543969 | Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | I |
| NCT04418167 | A Phase I Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations | I |
| NCT03635983 | A Phase III, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma. | III |
| NCT03470922 | A Randomized, Double-Blind Phase II/III Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma | II/III |
| NCT03711188 | A Study of the Safety and Efficacy of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma | II |
| NCT02339571 | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma | II/III |
| NCT02910700 | A Phase II Study of the TRiPlet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRiDeNT) | II |
| NCT03563729 | Efficacy Of Immunotherapy In Melanoma Patients With Brain Metastases Treated With Steroids | II |
| NCT02872259 | A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIC) or Metastatic (Stage IV) Melanoma. | I/II |

Clinical Trials Summary (continued)

BRAF p.(V600E) c.1799T>A (continued)

| NCT ID | Title | Phase |
|-------------|--|-------|
| NCT03332589 | A Phase I Study Of E6201 For The Treatment Of Central Nervous System Metastases (CNS) From BRAF Or MEK-Mutated Metastatic Melanoma | I |
| NCT03453034 | To Study the Pharmacokinetic Characteristics of TQ-B233 in the Human Body, Recommend a Reasonable Regimen for Subsequent Research | I |
| NCT04079166 | A Phase II Combination Study of SCIB1 with Pembrolizumab in Patients with Stage III or Stage IV Metastatic Melanoma | II |
| NCT03340129 | A Phase II, Open Label, Single Arm Study of Ipilimumab and Nivolumab With Salvage Radiotherapy in Patients With Melanoma Brain Metastases | II |
| NCT03875079 | An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), In Combination With Pembrolizumab (Anti-PD-1), In Participants With Advanced Or Metastatic Melanoma | I |
| NCT03905148 | A Phase Ib, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors | I/II |
| NCT02693535 | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | II |
| No NCT ID | Phase I study of the safety, tolerability, pharmacokinetics and preliminary efficacy of RX208 in patients with advanced malignant solid tumors | I |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial | II |
| NCT03155620 | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol | II |
| NCT03220035 | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase II Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations | II |
| NCT03781219 | A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor | I |
| NCT03239015 | Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event | II |
| NCT04045496 | A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors | I |
| NCT02407509 | A Phase I Trial of RO5126766 (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus | I |
| NCT04198818 | A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors | I/II |
| NCT03429803 | A Phase I Study of TAK-580 (MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors | I |
| NCT03634982 | A Phase I, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors | I |
| NCT03520075 | A Phase I/II Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors | I/II |
| NCT02857270 | A Phase I Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer | I |



Clinical Trials Summary (continued)

MYC amplification

| NCT ID | Title | Phase |
|-------------|---|-------|
| NCT03718091 | A Phase II Study of M6620 (VX-970) in Selected Solid Tumors | II |
| NCT03838042 | INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents with Refractory High-risk Malignancies | I/II |
| NCT03936465 | Phase I Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer | I |

Alerts Informed By Public Data Sources

Current NCCN Information

 Contraindicated
  Not recommended
  Resistance

NCCN information is current as of 2020-11-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

BRAF p.(V600E) c.1799T>A

trametinib

Cancer type: Melanoma

Variant class: BRAF V600E mutation

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "Although trametinib is FDA approved for single-agent use to treat patients with unresectable or metastatic melanoma with BRAF V600E mutation, trametinib monotherapy is no longer an NCCN recommended treatment option due to relatively poor efficacy compared with BRAF inhibitor monotherapy and BRAF/MEK inhibitor combination therapy."

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

dabrafenib + trametinib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "As the COMBI-AD trial excluded patients with distant metastases, dabrafenib/trametinib is not a recommended adjuvant treatment option for resected stage IV disease."

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 4.2020]

BRAF p.(V600E) c.1799T>A (continued)**— cetuximab****Cancer type:** Colon Cancer**Variant class:** BRAF V600E mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "BRAF V600E mutation makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor."

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 4.2020]**— cetuximab****Cancer type:** Rectal Cancer**Variant class:** BRAF V600E mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "BRAF V600E mutation makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor."

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 6.2020]**— panitumumab****Cancer type:** Colon Cancer**Variant class:** BRAF V600E mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "BRAF V600E mutation makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor."




Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 4.2020]**— panitumumab****Cancer type:** Rectal Cancer**Variant class:** BRAF V600E mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "BRAF V600E mutation makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor."

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 6.2020]

Current ESMO Information

 Contraindicated  Not recommended  Resistance

ESMO information is current as of 2020-11-02. For the most up-to-date information, search www.esmo.org.

BRAF p.(V600E) c.1799T>A

vemurafenib

Cancer type: Melanoma

Variant class: BRAF V600 mutation

Summary:

ESMO Clinical Practice Guidelines include the following supporting statement(s):

- "Efficacy of adjuvant targeted therapy has also been recently reported. The BRIM8 study analysed vemurafenib monotherapy versus a placebo in stage IIC and stage III (AJCC 7th edition) melanoma after complete surgical resection. The study did not meet its primary end point of DFS. Therefore, BRAF inhibitor monotherapy cannot be recommended as adjuvant treatment for melanoma".

Reference: ESMO Clinical Practice Guidelines - ESMO-Cutaneous Melanoma [Annals of Oncology 30: 1884–1901. doi:10.1093/annonc/mdz411]

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. Cheng et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. *Mod. Pathol.* 2018 Jan;31(1):24-38. PMID: 29148538
2. Alrabadi et al. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. *Mod. Pathol.* 2019 Mar;32(3):330-337. PMID: 30315274
3. Quan et al. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. *Journal of Translational Medicine*, 29 Aug 2019, 17(1):298. PMID: 31470866
4. Yao et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. *Nature*. 2017 Aug 10;548(7666):234-238. PMID: 28783719
5. Bracht et al. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. *Cancers (Basel)*. 2019 Sep 17;11(9). PMID: 31533235
6. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. *Cell*. 2014 Oct 23;159(3):676-90. PMID: 25417114
7. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
8. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012 Jul 18;487(7407):330-7. PMID: 22810696
9. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. PMID: 25079552
10. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
11. Wan et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell*. 2004 Mar 19;116(6):855-67. PMID: 15035987
12. Tiacci et al. BRAF mutations in hairy-cell leukemia. *N. Engl. J. Med.* 2011 Jun 16;364(24):2305-15. PMID: 21663470
13. Diamond et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Cancer Discov.* 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. Epub 2015 Nov 13. PMID: 26566875
14. Imielinski et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. *J Clin Invest.* 2014 Apr;124(4):1582-6. doi: 10.1172/JCI72763. Epub 2014 Feb 24. PMID: 24569458
15. Ciampi et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. *J. Clin. Invest.* 2005 Jan;115(1):94-101. PMID: 15630448
16. Palanisamy et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nat. Med.* 2010 Jul;16(7):793-8. PMID: 20526349
17. Jones et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Cancer Res.* 2008 Nov 1;68(21):8673-7. PMID: 18974108
18. Cin et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathol.* 2011 Jun;121(6):763-74. doi: 10.1007/s00401-011-0817-z. Epub 2011 Mar 20. PMID: 21424530
19. Ross et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. *Int. J. Cancer.* 2016 Feb 15;138(4):881-90. PMID: 26314551
20. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf
21. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf
22. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf
23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf
24. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210498s001lbl.pdf
25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf
26. <https://www.cmedresearch.com/post/2020-07-bvd-rare-oncology-phase2-trial/>
27. Villanueva et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. *Cell Rep.* 2013 Sep 26;4(6):1090-9. PMID: 24055054
28. Shi et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov.* 2014 Jan;4(1):80-93. PMID: 24265155
29. Rizos et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. *Clin. Cancer Res.* 2014 Apr 1;20(7):1965-77. PMID: 24463458

References (continued)

30. Kulkarni et al. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. *Clin. Cancer Res.* 2017 Sep 15;23(18):5631-5638. PMID: 28539463
31. Johnson et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. *Eur. J. Cancer.* 2015 Dec;51(18):2792-9. PMID: 26608120
32. Nazarian et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature.* 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24. PMID: 21107323
33. Shi et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. *Cancer Discov.* 2014 Jan;4(1):69-79. PMID: 24265152
34. Van et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discov.* 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21. PMID: 24265153
35. Chen et al. Targeting oncogenic Myc as a strategy for cancer treatment. *Signal Transduct Target Ther.* 2018 Feb 23;3:5. doi: 10.1038/s41392-018-0008-7. eCollection 2018. PMID: 29527331
36. Dang. MYC on the path to cancer. *Cell.* 2012 Mar 30;149(1):22-35. PMID: 22464321
37. Dominguez-Sola et al. Non-transcriptional control of DNA replication by c-Myc. *Nature.* 2007 Jul 26;448(7152):445-51. PMID: 17597761
38. Wahlström et al. Impact of MYC in regulation of tumor cell metabolism. *Biochim. Biophys. Acta.* 2015 May;1849(5):563-9. PMID: 25038584
39. Dang et al. The c-Myc target gene network. *Semin. Cancer Biol.* 2006 Aug;16(4):253-64. PMID: 16904903
40. Blackwood et al. Myc and Max function as a nucleoprotein complex. *Curr. Opin. Genet. Dev.* 1992 Apr;2(2):227-35. PMID: 1638116
41. Chakraborty et al. A common functional consequence of tumor-derived mutations within c-MYC. *Oncogene.* 2015 Apr 30;34(18):2406-9. PMID: 24998853
42. Xu-Monette et al. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. *Clin. Cancer Res.* 2016 Jul 15;22(14):3593-605. PMID: 26927665
43. Kalkat et al. MYC Deregulation in Primary Human Cancers. *Genes (Basel).* 2017 May 25;8(6). PMID: 28587062
44. Beroukhi et al. The landscape of somatic copy-number alteration across human cancers. *Nature.* 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822. PMID: 20164920
45. Taub et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. *Proc Natl Acad Sci U S A.* 1982 Dec;79(24):7837-41. PMID: 6818551
46. Ott et al. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. *Hematology Am Soc Hematol Educ Program.* 2013;2013:575-83. PMID: 24319234
47. Posternak et al. Strategically targeting MYC in cancer. *F1000Res.* 2016;5. PMID: 27081479
48. Carabet et al. Therapeutic Inhibition of Myc in Cancer. *Structural Bases and Computer-Aided Drug Discovery Approaches.* *Int J Mol Sci.* 2018 Dec 29;20(1). PMID: 30597997
49. Shahbazi et al. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. *Clin. Cancer Res.* 2016 May 15;22(10):2534-44. PMID: 26733615